1.De Angelis, R., et al., Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5—a population-based study. The lancet oncology, 2014. 15(1): p. 23–34.
2.Shi, Y. and Y. Sun, Manual Of Medical Oncology, ed. P.s.M. P. House. 2015: Ren min wei sheng chu ban she.
3.Sureban, S., et al., Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene, 2008. 27(33): p. 4544.
4.O’connell, R. M., et al., Physiological and pathological roles for microRNAs in the immune system. Nature Reviews Immunology, 2010. 10(2): p. 111.
5.Jonsson, L., et al., High RBM3 expression in prostate cancer independently predicts a reduced risk of biochemical recurrence and disease progression. Diagnostic pathology, 2011. 6(1): p. 91.
6.Yang, G., et al., RNA-binding protein quaking, a critical regulator of colon epithelial differentiation and a suppressor of colon cancer. Gastroenterology, 2010. 138(1): p. 231–240. e5.
7.Schneider, J., et al., mRNA expression of the putative antimetastatic gene BRMS1 and of apoptosis-related genes in breast cancer. Cancer Genomics-Proteomics, 2011. 8(4): p. 195–197.
8.Boman, K., et al., Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC urology, 2013. 13(1): p. 17.
9.Ye, F., et al., High RNA-binding motif protein 3 (RBM3) expression is independently associated with prolonged overall survival in intestinal-type gastric cancer. Medical science monitor: international medical journal of experimental and clinical research, 2017. 23: p. 6033.
10.Molina, J. R., et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. in Mayo Clinic Proceedings. 2008. Elsevier.
11.Tas, F., et al., Age is a prognostic factor affecting survival in lung cancer patients. Oncology letters, 2013. 6(5): p. 1507–1513.
12.Segal, R., K. Miller, and A. Jemal, Cancer statistics, 2018. CA Cancer J Clin, 2018. 68: p. 7–30.
13.Chen, K., et al., Comparison of the efficacy of concurrent chemoradiotherapy plus consolidation chemotherapy and sequential chemoradiotherapy in the treatment of elderly patients with stage III non-small cell lung cancer. Chinese Journal of Gerontology, 2014. 34(9): p. 2420–2421.
14.HU, H.-t., et al., Clinical observation on concurrent chemotherapy plus radiotherapy in treatment of stage Ⅲ non-small cell lung cancer [J]. Journal of Regional Anatomy and Operative Surgery, 2011. 1.
15.Derry, J. M., J. A. Kerns, and U. Francke, RBM3, a novel human gene in Xp11. 23 with a putative RNA-binding domain. Human molecular genetics, 1995. 4(12): p. 2307–2311.
16.Zhou, R.-B., et al., RNA binding motif protein 3: a potential biomarker in cancer and therapeutic target in neuroprotection. Oncotarget, 2017. 8(13): p. 22235.
17.Ehlén, Å., et al., Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. Journal of translational medicine, 2010. 8(1): p. 78.
18.Matsuda, A., et al., Generation of mice deficient in RNA-binding motif protein 3 (RBM3) and characterization of its role in innate immune responses and cell growth. Biochemical and biophysical research communications, 2011. 411(1): p. 7–13.
19.Zeng, Y., et al., Down‐regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity. Journal of cellular biochemistry, 2009. 107(1): p. 179–188.
20.Cok, S. J., et al., Identification of RNA-binding proteins in RAW 264.7 cells that recognize a lipopolysaccharide-responsive element in the 3-untranslated region of the murine cyclooxygenase–2 mRNA. Journal of Biological Chemistry, 2004. 279(9): p. 8196–8205.
21.Jögi, A., et al., Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer. Modern Pathology, 2009. 22(12): p. 1564.
22.Ma, R., et al., RNA binding motif protein 3 (RBM3) drives radioresistance in nasopharyngeal carcinoma by reducing apoptosis via the PI3K/AKT/Bcl–2 signaling pathway. American journal of translational research, 2018. 10(12): p. 4130.
23.Zeng, D., J. Hua, and Y. An, Expression and clinical significance of RBM3 in epithelial ovarian cancer. Nanchang University, 2016. 22(31): p. 14–15.